New pill shows promise for tough lung cancer
NCT ID NCT07231068
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new oral drug called dositinib in people with advanced non-small cell lung cancer that has a specific EGFR mutation. The trial has two parts: first, finding the safest dose, then testing that dose in a larger group. Researchers will monitor side effects, how the drug moves through the body, and whether it shrinks tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Dositinib mesylate tablets (90-1408)
What this could lead to
If successful, this could provide a new targeted treatment option for people with advanced EGFR-mutant lung cancer.
What could go wrong
This is an early-phase trial with small numbers, so safety and effectiveness are not yet proven. Side effects are possible, and the drug may not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences
RECRUITINGBeijing, China
-
Henan Provincial Cancer Hospital
RECRUITINGZhengzhou, China
-
Henan Provincial People's Hospital
RECRUITINGZhengzhou, China
-
Peking Union Medical College Hospital
WITHDRAWNBeijing, China
-
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
RECRUITINGGuangzhou, China